CCR5 antagonism in HIV infection: Ways, effects, and side effects

AIDS

Volumn 23, Issue 15, 2009, Pages 1931-1943

  Corbeau, Pierre ^a,b,c   Reynes, Jacques ^c,d,e  

^a NÎMES UNIVERSITY HOSPITAL   (France)

^b INSTITUTE OF HUMAN GENETICS   (France)

^c UNIV MONTPELLIER   (France)

^d GUI DE CHAULIAC HOSPITAL   (France)

^e UNIVERSITÉ DE MONTPELLIER   (France)

Author keywords

Antiretroviral therapy; CCR5 antagonists; CCR5 receptor; Chemokines; CXCR4 receptor; Maraviroc

Indexed keywords

APLAVIROC; CELL SURFACE PROTEIN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CCR5 ANTIBODY; ENFUVIRTIDE; GLYCOPROTEIN GP 120; HGS 004; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MARAVIROC; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HGS 004; PRO 140; RANTES; UNCLASSIFIED DRUG; VICRIVIROC;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; APOPTOSIS; DIMERIZATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TOLERABILITY; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LIVER TOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; RECEPTOR BLOCKING; REVIEW; T LYMPHOCYTE; TH1 CELL; VIRUS STRAIN;

DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP120; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; IMMUNE TOLERANCE; RECEPTORS, CCR5; T-LYMPHOCYTE SUBSETS;

EID: 70349758505     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32832e71cd     Document Type: Review

References (176)

1. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, et al. CC CKR5: A RANTES, MIP-1a, MIP-1b receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272:1955-1958.
2. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, et al. The b-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996; 85:1135-1148.
3. Deng H, Liu R, Ellmeier W, Choe S, Unumatz D, Burkhart M, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381:661-666.
4. Doranz BJ, Rucker J, Yi YJ, Smyth RJ, Samson M, Peiper SC, et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996; 85:1149-1158.
5. Dragic T, Litwin V, AllawayGP,Martin SR,Huang Y,Nagashima KA, et al. HIV-1 entry into CD4R cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381:667-673.
6. Samson M, Labbe O, Mollereau C, Vassart G, Parmentier M. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry 1996; 35:3362-3367. (Pubitemid 26092558)
7. Blanpain C, Migeotte I, Lee B, Vakili J, Doranz BJ, Govaerts C, et al. CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. Blood 1999; 94:1899-1905.
8. Ogilvie P, Bardi G, Clark-Lewis I, Baggiolini M, Uguccioni M. Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5. Blood 2001; 97:1920-1924.
9. Petkovic V, Moghini C, Paoletti S, Uguccioni M, Gerber B. ITAC/ CXCL11 is a natural antagonist for CCR5. J Leukoc Biol 2004; 76:701-708.
10. Cocchi F, De Vico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1a, and MIP-1b as the major HIV-suppressive factors produced by CD8R T cells. Science 1995; 270:1811.
11. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transembrane, G protein-coupled receptor. Science 1996; 272:872-877. (Pubitemid 26154590)
12. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996; 273:1856-1862.
13. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86:367-377.
14. Michael NL, Moore JP. HIV-1 entry inhibitors: Evading the issue. Nat Med 1999; 5:740-742.
15. Brumme ZL, Goodrich J, Mayer HB, Brumme CJ, Henrick BM, Wynhoven B, et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviralnaýve individuals. J Infect Dis 2005; 192:466-474.
16. Richman DD, Bozzette SA. The impact of the syncitiuminducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994; 169:968-974.
17. Bou-Habib DC, Rderiquez G, Oravecz T, Berman PW, Lusso P, Norcross MA. Cryptic nature of envelope V3 region epitopes protects monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J Virol 1994; 68:6006-6013.
18. Harouse JM, Buckner C, Gettie A, Fuller R, Bohm R, Blanchard J, et al. CD8R T cell-mediated CXC chemokine receptor 4- simian/human immunodeficiency virus suppression in dually infected rhesus macaques. Proc Natl Acad Sci USA 2003; 100:10977-10982.
19. Xiao X, Wu L, Stantchev TS, Feng YR, Ugolini S, Chen H, et al. Constitutive cell surface association between CD4 and CCR5. Proc Natl Acad Sci USA 1999; 96:7496-7501.
20. Manes S, Mira F, Gomez-Mouton C, Lacalle RA, Keller P, Labrador JP, et al. Membrane raft microdomain mediate front-rear polarity in migrating cells. EMBO J 1999; 18: 6211-6220.
21. Doranz BJ, Baik SS, Doms RW. Use of a gp120 binding assay to dissect the requirements and kinetics of human immunodeficiency virus fusion events. J Virol 1999; 73:10346-10358.
22. Glushakova S, Baibakov B, Margolis LB, Zimmerberg J. Infection of human tonsil histocultures: A model for HIV pathogenesis. Nat Med 1995; 1:1320-1322.
23. Rabut GEE, Konner JA, Kajumo F, Moore JP, Dragic T. Alanine substitutions of polar and nonpolar residues in the aminoterminal domain of CCR5 differently impair entry of macrophage- and dualtropic isolates of human immunodeficiency virus type 1. J Virol 1998; 72:3464-3468.
24. Thompson DAD, Cormier EG, Dragic T. CCR5 and CXCR4 usage by nonclade B human immunodeficiency virus type 1 primary isolates. J Virol 2002; 76:3059-3064.
25. Kuhmann SE, Platt EJ, Kozak SL, Kabat D. Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1. J Virol 2000; 74:7005-7015.
26. Rottman JB, Ganley KP, Williams K, WuL, Mackay CR, Ringler DJ. Cellular localization of the chemokine receptor CCR5. Correlation to cellular target HIV-1 infection. Am J Pathol 1997; 151:1341-1351.
27. Bleul CC, Su L, Hoxie JA, Springer TA, Mackay R. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci USA 1997; 94:1925-1930.
28. Lee B, Sharron M, Montaner LJ, Weissman D, Doms RW. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci USA 1999; 96:5215-5220.
29. Loetscher P, Uguccioni M, Bordoli L, Baggiolini M, Moser B, Chizzolini C, et al. CCR5 is characteristic of TH1 lymphocytes. Nature 1998; 391:344-345.
30. Reynes J, Portales P, Segondy M, Baillat V, André P, et al. CD4R T cell surface CCR5 density and virus load in persons infected with human immunodeficiency virus type 1. J Infect Dis 2000; 182:1285-1286.
31. Martin MP, Dean M, Smith MW, Winkler C, Gerrard B, Michael NL, et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 1998; 282:1907-1911.
32. McDermott DH, Zimmereman PA, Guignard F, Kleeberger CA, Leitman SF, the Multicenter AIDS Cohort Study (MACS). CCR5 promoter polymorphism and HIV-1 disease progression. Lancet 1998; 352:866-870.
33. Mummidi S, Ahuja SS, Gonzalez E, Anderson SA, Santiago EN, Stephan KT, et al. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nature Med 1998; 4: 786-793.
34. Mueller A, Kelly E, Strange PG. Pathways for internalization and recycling of the chemokine receptor CCR5. Blood 2002; 99:785-791. (Pubitemid 34525536)
35. Signoret N, Pelchen-Matthews A, Mack M, Proudfoot AE, Marsh M. Endocytosis and recycling of the HIV coreceptor CCR5. J Cell Biol 2000; 151:1281-1294.
36. Lin YL, Mettling C, Portalès P, Rouzier R, Clot J, Reynes J, et al. The chemokine CCL5 regulates the in vivo cell surface expression of its receptor, CCR5. AIDS 2008; 22:430-432.
37. Venkatesan R, Rose JJ, Lodge R, Murphy PM, Foley JF. Distinct mechanisms of agonist-induced endocytosis for human chemokine receptors CCR5 and CXCR4. Mol Biol Cell 2003; 14:3305-3324.
38. Singer I, Scott S, Kawka DW, Chin J, Daughery BL, DeMartino JA, et al. CCR5, CXCR4, and CD4 are clustered and closely apposed on microvilli of human macrophages and T cells. J Virol 2001; 75:3779-3790.
39. Steffens CM, Hope TJ. Localization of CD4 and CCR5 in living cells. J Virol 2003; 77:4985-4991.
40. Issafras H, Angers S, Bulenger S, Blanpain C, Parmentier M, Labbe-Julie C, et al. Constitutive agonist-independent CCR5 oligomerization and antibody-mediated clustering occuring at physiological levels of receptors. J Biol Chem 2002; 277:34666-34673.
41. Benkirane M, Willey R, Jin D-Y, Chun RF, Koup RA, Jeang K-T. Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by CCR5D32. J Biol Chem 1997; 272:30603-30606.
42. Mellado M, Rodriguez-Frade JM, Vila-Coro AJ, de Ana AM, Martinez-A C. Chemokine control of HIV-1 infection. Nature 1999; 400:723-724.
43. Suzuki S, Chuang LF, Yau P, Doi RH, Chuang RY. Interactions of opioid and chemokine receptors: Oligomerization of mu, kappa, and delta with CCR5 on immune cells. Exp Cell Res 2002; 280:192-200.
44. Ebert LM, McColl SR. Up-regulation of CCR5 and CCR6 on distinct subpopulations of antigen-activated CD4RT lymphocytes. J Immunol 2002; 168:65-72.
45. Carroll RG, Riley JL, Levine BL, Feng Y, Kaushal S, Ritchey DW, et al. Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4R T cells. Science 1997; 276:273-276.
46. Kinter A, Arthos J, Cicala C, Fauci AS. Chemokines, cytokines and HIV: A complex network of interactions that influence HIV pathogenesis. Immunol Rev 2000; 177:88-98.
47. Vassiliadou N, Tucker L, Anderson DJ. Progesterone-induced inhibition of chemokine receptor expression on peripheral blood mononuclear cells correlates with reduced HIV-1 infectability in vitro. J Immunol 1999; 162:7510-7518.
48. Anton PA, Elliott J, Poles MA, McGowan IM, Matud J, Hultin LE, et al. Enhanced levels of functional HIV-1 co-receptors on human mucosal T cells demonstrated using intestinal biopsy tissue. AIDS 2000; 14:1761-1765.
49. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, et al. CD4R T cell depletion during all stages of HIV disease occurred predominantly in the gastrointestinal tract. J Exp Med 2004; 200:749-759.
50. Lillard JW Jr, Boyaka PN, Taub DD, McGhee JR. RANTES potentiates antigen-specific mucosal immune responses. J Immunol 2001; 166:162-169.
51. Appay V, Dunbar PR, Cerundolo V,McMichael A, Czaplewski L, Rowland-Jones S. RANTES activates antigen-specific cytotoxic T lymphocytes in a mitogen-like manner through cell surface aggregation. Int Immunol 2000; 12:1173-1182.
52. Bacon KB, Premack BA, Gardner P, Schall TJ. Activation of dual T cell signaling pathways by the chemokine RANTES. Science 1995; 269:1727-1730.
53. Taub DD, Turkovski-Corrales SM, Key ML, Longo DL, Murphy WJ. Chemokines and T lymphocyte activation: I Beta chemokines costimulate human T lymphocyte activation in vitro. J Immunol 1996; 156:2095-2103.
54. Contento RL, Molon B, Boularan C, Pozzan T, Manes S, Mariullo S, et al. CXCR4-CCR5: A couple modulating T cell functions. Proc Natl Acad Sci USA 2008; 105:10101-10106.
55. Castellino F, Huang AY, Altan-Bonnet G, Stoll S, Scheineker C, Germain RN. Chemokines enhance immunity by guiding naive CD8R T cells to sites of CD4R T cell-dendritic cell interaction. Nature 2006; 440:890-895.
56. Hugues S, Scholer A, Boissonnas A, Nussbaum A, Combadière C, Amigorena S, et al. Dynamic imaging of chemokine-dependent CD8R T cell help for CD8R T cell responses. Nat Immunol 2007; 8:921-930.
57. Patterson BK, Czerniewski M, Andersson J, Sullivan Y, Su F, Jiyamapa D, et al. Regulation of CCR5 and CXCR4 expression by type 1 and 2 cytokines: CCR5 expression is downregulated by IL-10 in CD4-positive lymphocytes. Clin Immunol 1999; 91:254-262.
58. Schrum S, Probst P, Fleischer B, Zipfel PF. Synthesis of the CCchemokines MIP-1alpha, MIP-1beta, and RANTES is associated with a type 1 immune response. J Immunol 1996; 157:3598-3604.
59. Zou W, Borvak J, Marches F, Wei S, Galanaud P, Emilie D, et al. Macrophage-derived dendritic cells have strong Th1- polarizing potential mediated by beta-chemokines rather than IL-12. J Immunol 2000; 165:4388-4396.
60. Dorner BG, Scheffold A, Rolph MS, Huser BG, Kaufmann SH, Radbruch A, et al. MIP-1alpha, MIP-1beta, RANTES, and ATAC/lymphotactin function together with IFN-gamma as type 1 cytokines. Proc Natl Acad Sci USA 2002; 99:6181-6186.
61. Andres PG, Beck PL, Mizoguchi E, Mitzoguchi A, Bhan AK, Dawson TC, et al. Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sulfate-mediated colitis: Lack of CC chemokine receptor 5 expression results in a NK1.1R lymphocyte-associated Th2- type immune response in the intestine. J Immunol 2000; 164:6303-6312.
62. Zhou Y, Kurihara T, Ryseck R-P, Yang Y, Ryan C, Loy J, et al. Impaired macrophage function and enhanced T-cell dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor. J Immunol 1998; 160:4018-4025.
63. Nguyen GT, Carrington M, Beeler JA, Dean M, Aledort LM, Blatt PM, et al. Phenotypic expressions of CCR5-D32/D32 homozygosity. J Acquir Immune Defic Syndr 1999; 22: 75-82.
64. Mettimano M, Specchia ML, Ianni A, Arzani D, Ricciardi G, Savi L, et al. CCR5 and CCR2 gene polymorphisms in hypertensive patients. Br J Biomed Sci 2003; 60:19-21.
65. Zlotnik A, Yoshie O. Chemokines: A new classification system and their role in immunity. Immunity 2000; 12: 121-127.
66. Floto RA, MacAry PA, Boname JM, Mien TS, Kampmann B, Hair JR, et al. Dendritic cell stimulation by mycobacterial Hsp70 is mediated through CCR5. Science 2006; 314:454-458.
67. Aliberti J, Valenzuela JG, Carruthers VB, Hieny S, Andersen J, Charest H, et al. Molecular mimicry of a CCR5 bindingdomain in the microbial activation of dendritic cells. Nat Immunol 2003; 4:485-490.
68. Rahbar R, Murooka TT, Huinek AA, Galligan CL, Sassano A, Yu C, et al. Vaccinia virus activation of CCR5 invokes tyrosine phosphorylation signaling events that support virus replication. J Virol 2006; 80:7245-7259.
69. Huffnagel GB, McNeil LK, McDonald RA, Murphy JW, Toews GB, Maeda N, et al. Role of C-C chemokine receptor 5 in organ-specific and innate immunity to Cryptococcus neoformans. J Immunol 1999; 163:4642-4646.
70. Luangsay S, Kasper LH, Rachinel N, Minns LA, Mennechet FJ, Vandewalle A, et al. CCR5 mediates specific migration of Toxoplasma gondii-primed CD8 lymphocytes to inflammatory intestinal epithelial cells. Gastroenterology 2003; 125: 491-500.
71. Dawson TC, Beck MA, Kuziel WA, Henderson F, Maeda N. Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus. Am J Pathol 2000; 156:1951-1959.
72. Thapa M, Kuziel WA, Carr DJJ. Susceptibility of CCR5- deficient mice to genital herpes simplex virus type 2 is linked to NK cell mobilization. J Virol 2007; 81:3704-3713.
73. Machado FS, Koyama NS, Carregaro V, Ferreira BR, Milanezi CM, Teixeira MM, et al. CCR5 plays a critical role in the development of myocarditis and host protection in mice infected with Trypanosoma cruzi. J Infect Dis 2005; 4:627-636.
74. Barr EL, Ouburg S, Igietseme JU, Morré SA, Okwandu E, Eko FO, et al. Host inflammatory response and development of complications of Chlamydia trachomatis genital infection in CCR5-deficient mice and subfertile women with the CCR5delta32 gene deletion. J Microbiol Immunol Infect 2005; 38:244-254.
75. Hull J, Rowlands K, Lockhart E, Moore C, Sharland M, Kwiatkowski D. Variants of the chemokine CCR5 are associated with severe bronchiolitis caused by respiratory syncytial virus. J Infect Dis 2003; 188:904-907.
76. Glass WG, McDermott DH, Lim JK, Lekhong S, Yu SF, Frank WA, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 2006; 203:35-40.
77. Kindberg E, Mickiene A, Ax C, Akerlind B, Vene S, Lindquist L, et al. A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. J Infect Dis 2008; 197:266-269.
78. Woitas RP, Ahlenstiel G, Iwan A, Rockstroh JK, Brackmann HH, Kupfer B, et al. Frequency of the HIV-protective CC chemokine receptor 5-D32/D32 phenotype is increased in hepatitis C. Gastroenterology 2002; 122:1721-1728.
79. Ahlenstiel G, Berg T, Woitas RP, Grunhage F, Iwan A, Hess L, et al. Effects of the CCR5-D32 mutation on antiviral treatment in chronic hepatitis. J Hepatol 2003; 39:245-252.
80. Klein RS. Discussion on frequency of the HIV-protective CC chemokine receptor 5-D32/D32 genotype is increased in hepatitis C. Gastroenterology 2003; 124:1558.
81. Mangia A, Santoro R, D'agruma L, Andriulli A. HCV chronic infection and CCR5-D32/D32. Gastroenterology 2003; 124: 868-869.
82. Poljak M, Seme K, Marin IJ, Babic DZ, Matcic M, Meglic J. Frequency of the 32-base pair deletion in the chemokine receptor CCR5 gene is not increased in hepatitis C patients. Gastroenterology 2003; 124:1558-1560.
83. Promrat K, McDermott DH, Gonzalez CM, Kleiner DE, Koziol DE, Lessie M, et al. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology 2003; 124:352-360.
84. Zhang M, Goedert JJ, O'Brien TR. High frequency of CCR5- D32 homozygosity in HCV-infected, HIV-1-uninfected hemophiliacs results from resistance to HIV-1. Gastroenterology 2003; 124:867-868.
85. Belnoue E, Kayibanda M, Deschemin JC, Viguier M, Mack M, Kuziel WA, et al. CCR5 deficiency decreases susceptibility to experimental cerebral malaria. Blood 2003; 101:4253-4259.
86. Glass WG, Liu MT, Kuziel WA, Lane TE. Reduced macrophage infiltration and demyelination in mice lacking the chemokine receptor CCR5 following infection with a neurotropic coronavirus. Virology 2001; 288:8-17.
87. Moreira AP, Cavassani KA, Massafera Tristao FS, Campanelli AP, Martinez R, Rossi MA, et al. CCR5-dependent regulatory T cell migration mediates fungal survival and severe immunosuppression. J Immunol 2008; 180:3049-3056.
88. Cooke SP, Forrest G, Venables PJW, Hajeer A. The D32 deletion of CCR5 receptor in rheumatoid arthritis. Arthritis Rheumatol 1998; 41:1135-1136.
89. Gomez-Reino JJ, Pablos JL, Carreira PE, Santiago B, Serrano L, Vicario JL, et al. Association of rheumatoid arthritis with a functional chemokine receptor, CCR5. Arthritis Rheum 1999; 42:989-992.
90. Zapico I, Coto E, Rodriguez A, Alvarez C, Torre JC, Alvarez V. CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis. Genes Immun 2000; 1:288-289.
91. Garred P, Madsen HO, Petersen J, Marquart H, Hansen TM, Sorensen SF, et al. CC chemokine receptor 5 polymorphism in rheumatoid arthritis. J Rheumatol 1998; 25:1462-1465.
92. Quinone MP, Martinez HG, Jimenez F, Estrada CA, Dudley M, Willmon O, et al. CC ckemokine receptor 5 influences late stage atherosclerosis. Atherosclerosis 2007; 195:e92-e103.
93. Zernecke A, Liehn EA, Gao JL, Kuziel WA, Murphy PM, Weber C. Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice: Involvement of IL-10. Blood 2006; 107:4240-4243.
94. Veillard NR, Kwak B, Pelli G, Mulhaupt F, James RW, Proudfoot AE, et al. Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res 2004; 94:253-261.
95. Fischereder M, Luckow B, Hocher B, Wuthrich RP, Rothenpieler U, Schneeberger H, et al. CC chemokine receptor 5 and renal-transplant survival. Lancet 2001; 357:1758-1761.
96. Abdi R, Tran TB, Sahagun-Ruiz A, Murphy PM, Brenner BM, Milford EL, et al. Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J Am Soc Nephrol 2002; 13:754-758.
97. Schroder C, Pierson RNr, Nguyen BN, Kawka DW, Peterson LB, Wu G, et al. CCR5 blockade modulates inflammation and alloimmunity in primates. J Immunol 2007; 179:2289-2299.
98. Hall IP, Wheatley A, Christie G, McDougall C, Hubbard R, Helms PJ. Association of CCR5 D32 with reduced risk of asthma. Lancet 1999; 354:1264-1265.
99. Mitchell TJ, Walley AJ, Pease JE, Venables PJW, Wiltshire S, Williams TJ, et al. Delta32 deletion of CCR5 gene and association with asthma or atopy. Lancet 2000; 356:1491-1492.
100. Nagy A, Kozma GT, Bojszko A, Krikovszky D, Falus A, Szalai C. No association between asthma or allergy and the CCR5Delta 32 mutation. Arch Dis Child 2002; 86:426.
101. Sandford AJ, Zhu S, Bai TR, Fitzgerald JM, Pare PD. The role of the C-C chemokine receptor-5 Delta32 polymorphism in asthma and in the production of regulated on activation, normal T cells expressed and secreted. J Allergy Clin Immunol 2001; 108:69-73.
102. Lenzsch S, Gries M, Janz M, Bargou R, Dorken B, Mapara MY. Macrophage inflammatory protein 1-alpha (MIP-1a) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 2003; 101:3568-3573.
103. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumor stroma promote breast cancer metastasis. Nature 2007; 449:557-563.
104. Lavergne E, Combadière C, Iga M, Boissonnas A, Bonduelle O, Maho M, et al. Intratumoral CC chemokine ligand 5 overexpression delays tumor growth and increases tumor infiltration. J Immunol 2004; 173:3755-3762.
105. Manes S, Mira E, Colomer R, Montero S, Real LM, Gómez- Moutón C, et al. CCR5 expression influences the progression of human cancer in a p53-dependent manner. J Exp Med 2003; 198:1381-1389.
106. Castonguay LA, Weng Y, Adolfsen W, Di Salvo J, Kilburn R, Caldwell CG, et al. Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1,3, 4-trisubstituted pyrrolidines to human CCR5: A molecular modeling-guided mutagenesis study of the binding pocket. Biochemistry 2003; 42:1544-1550.
107. Tsamis F, Gavrilov S, Kajumo F, Seibert C, Kuhmann S, Ketasz T, et al. Analysis of the mechanism by which the smallmolecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol 2003; 77:5201-5208.
108. Muniz-Medina VM, Jones S, Maglich JM, Galardi C, Hollingsworth RE, Kazmierski WM, et al. The relative activity of 'function sparing' HIV-1 entry inhibitors on viral entry and CCR5 internalization: Is allosteric functional selectivity a valuable therapeutic property ? Mol Pharmacol 2008; 75: 490-501.
109. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359:1429-1441.
110. Nichols WG, Steel HM, Bonny T, Adkinson K, Curtis L, Millard J, et al. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother 2008; 52:858-865.
111. Esté JA, Telenti A. HIV entry inhibitors. Lancet 2007; 370:81-88.
112. Jacobson JM, Saag MS, Thompson MA, Fischl MA, Liporace R, Reichman RC, et al. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. J Infect Dis 2008; 198:1345-1352.
113. Lalezari J, Yadavalli GK, Para M, Richmond G, DeJesus E, Brown SJ, et al. Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients. J Infect Dis 2008; 197:721-727.
114. Cairns JS, D'Souza MP. Chemokines and HIV-1 s receptors: the therapeutic connection. Nat Med 1998; 4:563-568.
115. Gaertner H, Cerini F, Escola JM, Kuenzi G, Melotti A, Offord R, et al. Highly potent, fully recombinant anti-HIV chemokines: Reengineering a low-cost microbicide. Proc Natl Acad Sci USA 2008; 105:17706-17711.
116. Lelièvre J-D, Petit F, Perrin L, Mammano F, Arnoult D, Ameisen JC, et al. The density of coreceptors at the surface of CD4R T cells contributes to the extent of human immunodeficiency virus type 1 viral replication-mediated T cell death. AIDS Res Hum Retroviruses 2004; 20:1230-1243.
117. Madani N, Hubicki AM, Perdigoto AL, Springer M, Sodroski J. Inhibition of human immunodeficiency virus envelope glycoprotein- mediated single cell lysis by low-molecular-weight antagonists of viral entry. J Virol 2007; 81:532-538.
118. Tremblay CL, Giguel F, Kollmann C, Guan Y, Chou TC, Baroudy BM, et al. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob Agents Chemother 2002; 46:1336-1339.
119. Gervaix A, Nicolas J, Portales P, Posfay-Barbe K, Wyler CA, Segondy M, et al. Response to treatment and disease progression linked to CD4R T cell surface CCR5 density in HIV-1 vertical infection. J Infect Dis 2002; 185:1055-1061.
120. Vincent T, Portales P, Baillat V, Eden A, Clot J, Reynes J, et al. The immunological response to highly active antiretroviral therapy is linked to CD4R T-cell surface CCR5 density. J Acquir Immune Defic Syndr 2006; 43:377-378.
121. Reeves JD, Gallo SA, Ahmad N, Miamidian JL, Harvey PE, Sharron M, et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci USA 2002; 99:16249-16254.
122. Heredia A, Gilliam B, DeVico A, Le N, Bamba D, Flinko R, et al. CCR5 density levels on primary CD4 T cells impact the replication and enfuvirtide susceptibility of R5 HIV-1. AIDS 2007; 21:1317-1322.
123. Agrawal L, Lu X, Qingwen J, VanHorn-Ali Z, Nicolescu IV, McDermott DH, et al. Role of CCR5D32 protein in resistance to R5, R5X4, and X4 human immunodeficiency virus type 1 in primary CD4R cells. J Virol 2004; 78:2277-2287.
124. de Roda Husman A-M, Koot M, Cornelissen M, Keet IP, Brouwer M, Broersen SM, et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 1997; 127:882-890.
125. D'aquila RT, Sutton L, Savars A, Hughes MD, Johnson VA. CCR5/delta(ccr5) heterozygosity: A selective pressure for the syncitium-inducing human immunodeficiency virus type 1 phenotype. J Infect Dis 1998; 177:1549-1553.
126. Zhang L, He T, Huang Y, Chen Z, Guo Y, Wu S, et al. Chemokine receptor usage by diverse primary isolates of human immunodeficiency virus type 1. J Virol 1998; 72:9307-9312.
127. Mosier DE, Picchio GR, Gulizia RJ, Sabbe R, Poignard P, Picard L, et al. Highly potent RANTES analogues either prevent CCR5-using HIV-1 infection in vivo or rapidly select for CXCR4-using variants. J Virol 1999; 73:3544-3550.
128. Maeda Y, Foda M, Matsushita S, Harada S. Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha. J Virol 2000; 74:1787-1793.
129. Aarons EJ, Beddows S, Willingham T, Wu L, Koup RA. Adaptation to blockade of human immunodeficiency virus type 1 entry imposed by the anti-CCR5 monoclonal antibody 2D7. Virology 2001; 287:382-390.
130. Trkola A, Kuhmann SE, Strizki JM, Maxwell E, Ketas T, Morgan T, et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci USA 2002; 99:395-400.
131. Wolinsky SM, Veazy RS, Kunstman KJ, Klasse PJ, Dufour J, Marozsan AJ, et al. Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses. Virology 2004; 328:19-29.
132. Fatkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008; 359:1442-1455.
133. Lewis ME, Van der Ryst E, Youle M, Youle M, Jenkins T, James I, et al. Phylogenetic analysis and co-receptor tropism of HIV- 1 envelope sequences from patients with emergence of CXCR4 using virus following treatment with the CCR5 antagonist UK-427,857. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington [Late- Breaker Abstract H-548b] 2004.
134. Westby M, Lewis M, Withcomb J, Youle M, Pozniak AL, James IT, et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV- 1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006; 80:4909-4920.
135. Westby M, Smith-Burchnell C, Mori J, Lewis M, Mosley M, Stockdale M, et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007; 81:2359-2371.
136. Boyd MT, Simpson GR, Cann AJ, Johnson MA, Weiss RA. A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1gp120 alters cellular tropism. J Virol 1993; 67:3649-3652.
137. Dejucq N, Simmons G, Clapham PR. Expanded tropism of primary human immunodeficiency virus type 1 R5 strains to CD4(R) T-cell lines determined by their capacity to exploit low concentrations of CCR5. J Virol 1999; 73:7842-7847.
138. Bieniasz PD, Fridell RA, Aramori I, Ferguson SSG, Caron MG, Cullen BR. HIV-1-induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 coreceptor. EMBO J 1997; 16:2599-2609.
139. Edinger AL, Amedee A, Miller K, Doranz BJ, Endres M, Sharron M, et al. Differential utilization of CCR5 by macrophage and T cell tropic Simian Immunodeficiency Virus strains. Proc Natl Acad Sci USA 1997; 94:4005-4010.
140. Rucker J, Samson M, Doranz BJ, Libert F, Berson JF, Yi Y, et al. Regions on b-chemokine receptors CCR5 and CCR2b that determine HIV-1 corfactor specificity. Cell 1996; 87:437-446.
141. Agrawal L, VanHorm-Ali Z, Berger EA, Alkhatib G. Specific inhibition of HIV-1 coreceptor activity by synthetic peptides corresponding to the predicted extracellular loops of CCR5. Blood 2004; 103:1211-1217.
142. Repits J, Fenyo EM, Jansson M. Studies on the evolution of receptor use by HIV-1 R5 viruses isolated from AIDS patients. XV International AIDS Conference; 2004 [Abstract Tu- PeA4326].
143. Soulié C, Malet I, Lambert-Niclot S, Tubiana R, Thévenin M, Simon A, et al. Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients. AIDS 2008; 22:2212-2214.
144. Tsibris AM, Sagar M, Gulick RM, Su Z, Hughes M, Greaves W, et al. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol 2008; 82:8210-8214.
145. Riley J, Huang W, Wojcik L, Xu S, Kuhmann S, Moore JP, et al. HIV resistance to CCR5 antagonists requires multiple mutations and is associated with reduced replication capacity. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington [Abstract H-192] 2004.
146. Anastassopoulou CG, Marozsan AJ, Matet A, Snyder AD, Arts EJ, Kuhmann SE, et al. Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss. PLoS Pathog 2007; 3:e79.
147. Tsibris AM, Paredes R, Chadburn A, Su Z, Henrich TJ, Krambrink A, et al. Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: Results of the AIDS Clinical Trials Group A5211. Clin Infect Dis 2009; 48:642-649.
148. Landovitz RJ, Angel JB, Hoffmann C, Horst H, Opravil M, Long J, et al. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. J Infect Dis 2008; 198:1112-1122.
149. Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, Jacobson LP, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179:859-870.
150. Cartier C, Dubois-Dauphin M, Hartley O, Irminger-Finger I, Krause KH. Chemokine-induced cell death in CCR5-expressing neuroblastoma cells. Neuroimmunol 2003; 145:27-39.
151. Murooka TT, Wong MM, Rahbar R, Majchrzak-Kita B, Proudfoot AE, Fish EN. CCL5-CCR5-mediated apoptosis in T cells: Requirement for glycosaminoglycan binding and CCL5 aggregation. J Biol Chem 2006; 281:25184-25194.
152. Dolan MJ, Kulkarni H, Camargo JF, He W, Smith A, Anaya JM, et al. CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat Immunol 2007; 8:1324-1336.
153. Pandrea I, Apetrei C, Gordon S, Barbercheck J, Dufour J, Bohm R, et al. Paucity of CD4RCCR5R T cells is a typical feature of natural SIV hosts. Blood 2007; 109:1069-1076.
154. Saag M, Ive P, Heera J, Tawadrous M, DeJesus E, Clumeck N, et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with combivir (zidovudine/lamivudine), for the treatment of antiretroviral-naive subjects infected with R5 HIV 1: Week 48 results of the MERIT study. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Sydney; 2007 [Abst. WESS104].
155. Wilkin T, Ribaudo H, Gulick R. The relationship of CCR5 inhibitors to CD4 count changes: A meta-analysis of recent clinical trials in treatment-experienced subjects. 15th Conference on Retroviruses and Opportunistic Infections; Boston; 2008 [Abst.800].
156. Gulick RM, Su Z, Flexner C, Hughes MD, Skolnik PR, Wilkin TJ, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007; 196:304-312.
157. Bouhlal H, Hocini H, Quillent-Gregoire C, Donkova V, Rose S, Amara A, et al. Antibodies to C-C chemokine receptor 5 in normal human IgG block infection of macrophages and lymphocytes with primary R5-tropic strains of HIV-1. J Immunol 2001; 166:7606-7611.
158. Greene E, Pinto LA, Kwak-Kim JY, Giorgi JV, Landay AL, Kessler HA, et al. Increased levels of anti-CCR5 antibodies in sera from individuals immunized with allogenic lymphocytes. AIDS 2000; 14:2627-2628.
159. Lopalco L, Barassi C, Pastori C, Longhi R, Burastero SE, Tambussi G, et al. CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 in vitro. J Immunol 2000; 164:3426-3433.
160. Zuber B, Hinkula J, Vodros D, Lundholm P, Nilsson C, Morner A, et al. Induction of immune responses and break of tolerance by DNA against the HIV-1 coreceptor CCR5 but no protection from SIVsm challenge. Virology 2000; 278:400-411.
161. Wang Y, Tao L, Mitchell E, Bravery C, Berlingieri P, Armstrong P, et al. Allo-immunization elicits CD8R T cell-derived chemokines. HIV suppressor factors and resistance to HIV infection in women. Nat Med 1999; 5:1004-1009.
162. Lehner T, Wang L, Cranage M, Tao L, Mitchell E, Bravery C, et al. Up-regulation of b-chemokines and down-modulation of CCR5 co-receptors inhibit simian immunodeficiency virus transmission in nonhuman primates. Immunology 2000; 99: 569-577.
163. Heredia A, Davis C, Amoroso A, Dominique JK, Le N, Klingebiel E, et al. Induction of G1 cycle arrest in T lymphocytes results in increased extracellular levels of b-chemokines: A strategy to inhibit R5 HIV-1. Proc Natl Acad Sci USA 2003; 100:4179-4184.
164. Rodriguez-Frade JM, Del Real G, Serrano A, Hernanz-Falcon P, Soriano SF, Vila-Coro AJ, et al. Blocking HIV-1 infection via CCR5 and CXCR4 receptors by acting in trans on the CCR2 chemokine receptor. EMBO J 2004; 23:66-76.
165. Shen W, Li B, Wetzel MA, Rogers TJ, Henderson EE, Su SB, et al. Down-regulation of the chemokine receptor CCR5 by activation of chemotactic formyl peptide receptor in human monocytes. Blood 2000; 96:2887-2894.
166. Gilliam BL, Heredia A, Devico A, Le N, Bamba D, Bryant JL, et al. Rapamycin reduces CCR5 mRNA levels in macaques: Potential applications in HIV-1 prevention and treatment. AIDS 2007; 21:2108-2110.
167. Heredia A, Amoroso A, Davis C, Le N, Reardon E, Dominique JK, et al. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: An approach to suppress R5 strains of HIV-1. Proc Natl Acad Sci USA 2003; 100:10411-10416.
168. Thivierge M, Le Gouill C, Tremblay MJ, Stankova J, Rola- Pleszcynski M. Prostaglandin E2 induces resistance to human immunodeficiency virus-1 infection in monocyte-derived macrophages: Downregulation of CCR5 expression by cyclic adenosine monophosphate. Blood 1998; 92:40-45.
169. Nabatov AA, Pollakis G, Linnemann T, Paxton WA, de Baar MP. Statins disrupt CCR5 and RANTES expression levels in CD4R T lymphocytes in vitro and preferentially decrease infection of R5 versus X4 HIV-1. PLoS ONE 2007; 5:e470.
170. Moncunill G, Negredo E, Bosch L, Vilarrasa J, Witvrouw M, Llano A, et al. Evaluation of the anti-HIV activity of statins. AIDS 2005; 19:1697-1700.
171. Juffermas NP, Verbon A, Olszyna DP, van Deventer SJ, Speelman P, van Der Poll T. Thalidomide suppresses up-regulation of human immunodeficiency virus coreceptors CXCR4 and CCR5 on CD4RT cells in human. J Infect Dis 2000; 181:1813-1816.
172. Saccani A, Saccani S, Orlando S, Sironi M, Bernasconi S, Ghezzi P, et al. Redox regulation of chemokine receptor expression. Proc Natl Acad Sci USA 2000; 97:2761-2766.
173. Steinberger P, Andris-Widhopf J, Buhler B, Torbett BE, Barbas CFr. Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5- dependent HIV-1 infection and cell fusion. Proc Natl Acad Sci USA 2000; 97:805-810.
174. Yang A-G, Bai X, Huang XF, Yao C, Chen S-Y. Phenotype knock-out of HIV type 1 chemokine receptor CCR-5 by intrakines as potential therapeutic approach for HIV-1 infection. Proc Natl Acad Sci USA 1997; 94:11567-11572.
175. Gonzalez MA, Serrano F, Llorente M, Abad JL, Garcia-Ortiz MJ. A hammerhead ribozyme targeted to the human chemokine receptor CCR5. Biochem Biophys Res Commun 1998; 251:592-596.
176. Qin XF, An DS, Chen IS, Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA 2002; 100:183-188.